Hoofddorp, the Netherlands, 31 May 2020. IGEA Pharma N.V. (SIX: IGPH) today announced the disclosure of its Annual Report 2019.
Hoofddorp, the Netherlands, 6 May 2020. IGEA Pharma N.V. (SIX: IGPH) today announced that an evaluation by the Histocompatibility Laboratories, Department of Surgery, University of Miami – Miller School of Medicine suggests that the IGEA’s COVID-19 antibody rapid test appears to be superior to an established ELISA procedure in detecting IgM and IgG antibodies.
Hoofddorp, the Netherlands, 4 May 2020. IGEA Pharma N.V. (SIX: IGPH) today announced a further extension of the partnership with Acalis by signing an agreement for the wholesale distribution of the Alzheimer’s prevention kit ‘Alz1’ in the US.
Hoofddorp, the Netherlands, 30 April 2020. IGEA Pharma (SIX: IGPH) today announced the grant of a temporary exemption from its disclosure obligations with respect to the 2019 annual report.
Hoofddorp, the Netherlands, 6 April 2020. IGEA Pharma (SIX: IGPH) today announced to starting supply of a COVID-19 antibody test following an agreement signed with a PRC independent SARS-CoV-2 IgM/IgG test developer and manufacturer.
Hoofddorp, the Netherlands, 18 March 2020. IGEA Pharma (SIX: IGPH) today announced an explosion in the demand for dry aerosol devices in Italy as a result of the COVID-19 outbreak so severely affecting this country.
Hoofddorp, the Netherlands, 12 February 2020. IGEA Pharma N.V. (SIX: IGPH) today announced its intention to acquire a majority stake in Medical Jet Srl (“Medical Jet”), a privately held company operating in the pathogen’s decontamination of air and inanimate environmental surfaces and in air
sterilization and purification. A memorandum of understanding has been signed and subject to the satisfaction of certain customary conditions for a transaction of this type, IGEA expect to close the acquisition by June 2020. Further details of the transaction were not disclosed at this stage.
The international healthcare group Acalis intends to distribute IGEA’s tests kits and dietary supplements along with Meditalia’s polymeric based med-tech products.
Minutes of the Extraordinary General Meeting of IGEA Pharma N.V., a public limited company (naamloze vennootschap), having its registered office in Amsterdam (the Netherlands) and address at (2132 WT) Hoofddorp, Siriusdreef 17, registered with the Commercial Register of the Chamber of Commerce under number 70212821, held at Hoofddorp Transpolis, Polarisavenue 1, (2123 JH) Hoofddorp (the Netherlands) on 8 January 2020.